Background Surgical revascularization is an established indication for patients with advanced coronary artery disease and reduced left ventricular ejection fraction (LVEF). Long-term outcomes for these patients are not well defined. We studied the long-term outcomes of patients with ischaemic cardiomyopathy who underwent surgical revascularization in a well-defined nationwide cohort. Materials and methods A retrospective study on 2,005 patients that underwent isolated coronary artery bypass grafting (CABG) in Iceland between 2000–2016. Patients were catagorized into two groups based on their preoperative LVEF; LVEF ≤35% (n = 146, median LVEF 30%) and LVEF >35% (n = 1859, median LVEF 60%). Demographics and major adverse cardiac and cerebrovascular events (MACCE), were compared between groups along with cardiac-specific and overall survival. Mean follow-up was 7.6 years. Results Demographics were similar in both groups regarding age, gender, and most cardiovascular risk factors. However, patients with LVEF ≤35% more often had diabetes, renal insufficiency, chronic obstructive pulmonary disease and a previous history of myocardial infarction. Thirty-day mortality was four times higher (8% vs 2%, p < 0.001) in the LVEF ≤35%-group compared to controls. MACCE-free survival was 83% and 62% at 1 and 5 years for LVEF ≤35%-group compared to 94% and 82% for the control group. Overall survival was also significantly lower in the same groups, or 87% and 69% (p < 0.001) compared to 98% and 91% (p < 0.001), at 1 and 5 years respectively. Conclusions A good long-term outcome after CABG can be expected for patients with reduced LVEF, however, their survival is still significantly inferior to patients with normal ventricular function.

Arthritis induced by immune checkpoint inhibitors (ICPi) has been reported to occur in 1% to 7% of ICPi-treated patients with cancer.1-4Treatment generally starts with glucocorticoids (GCs) before disease-modifying antirheumatic drugs (DMARDs) are considered.5